
-
Bank of Japan holds rates, says to slow bond purchase taper
-
Empty seats as Chelsea win opener at Club World Cup, Benfica deny Boca
-
G7 urges Iran de-escalation as Trump makes hasty summit exit
-
Verdict due for Sweden's 'Queen of Trash' over toxic waste
-
Israel, Iran trade missile fire as Trump warns Tehran to 'evacuate'
-
Thunder hold off Pacers to take 3-2 NBA Finals lead
-
Soft power: BTS fans rally behind Korean international adoptees
-
Dominant Flamengo open with victory at Club World Cup
-
Oil prices jump after Trump's warning, stocks extend gains
-
UK MPs eye decriminalising abortion for women in all cases
-
Yen slides ahead of Bank of Japan policy decision
-
Ecuador pipeline burst stops flow of crude
-
China's Xi in Kazakhstan to cement Central Asia ties
-
Despite law, US TikTok ban likely to remain on hold
-
Venezuela's El Dorado, where gold is currency of the poor
-
US forces still in 'defensive posture' in Mideast: White House
-
Trump makes hasty summit exit over Iran crisis
-
OpenAI wins $200 mn contract with US military
-
AFP photographer shot in face with rubber bullet at LA protest
-
Boca denied by two Argentines as Benfica fight back
-
Rise in 'harmful content' since Meta policy rollbacks: survey
-
Trump to leave G7 early after warning of Iran attack
-
'Strange' to play in front of 50,000 empty seats: Chelsea's Maresca
-
Netanyahu says 'changing face of Middle East' as Israel, Iran trade blows
-
Mexican band accused of glorifying cartels changes its tune
-
G7 leaders urge Trump to ease off trade war
-
Trump presses Iran to talk but holds back on joint G7 call
-
Colombia presidential hopeful 'critical' after shooting
-
Main doctor charged in actor Matthew Perry overdose to plead guilty
-
Chelsea defeat LAFC in poorly-attended Club World Cup opener
-
Tiafoe crashes out, Rune cruises through at Queen's Club
-
Netanyahu says campaign 'changing face of Middle East' as Israel, Iran trade blows
-
What's not being discussed at G7 as Trump shapes agenda
-
UK apologises to thousands of grooming victims as it toughens law
-
Iran state TV briefly knocked off air by strike after missiles kill 11 in Israel
-
Trump urges Iran to talk as G7 looks for common ground
-
Canada wildfire near Vancouver contained
-
Four Atletico ultras get suspended jail for Vinicius effigy
-
England's top women's league to expand to 14 teams
-
Oil prices drop, stocks climb as Iran-Israel war fears ease
-
UN refugee agency says will shed 3,500 jobs due to funding cuts
-
US moves to protect all species of pangolin, world's most trafficked mammal
-
Kneecap 'unfazed' by legal problems, says friend and director
-
Electric fences, drones, dogs protect G7 leaders from bear attack
-
The name's Metreweli... Who is UK MI6's first woman chief?
-
Oil prices fall, stocks rise as Iran-Israel war fears ease
-
Fighter jets, refuelling aircraft, frigate: UK assets in Mideast
-
Iranian Nobel laureates, Cannes winner urge halt to Iran-Israel conflict
-
Struggling Gucci owner's shares soar over new CEO reports
-
Khamenei, Iran's political survivor, faces ultimate test

Biden proposes huge expansion of weight loss drug access
Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald Trump's incoming health chief looked set to shoot down the idea.
Under the massive US public health insurance programs Medicare and Medicaid, drugs like Ozempic and Wegovy are, for the most part, only available for overweight people with diabetes or heart disease.
But the White House said Biden wanted to make the game-changing medications widely available as a treatment for obesity itself -- expanding coverage to nearly 7.5 million older and lower-income Americans.
"For too many Americans, these critical treatments are too expensive and therefore out of reach," a White House official said, noting that 42 percent of Americans are obese.
The Department of Health and Human Services said separately in a statement that the "transformative medications" would improve the "health and quality of life for millions of people who have obesity."
The move would benefit 3.4 million Americans with Medicare, which gives health insurance to people mainly aged over 65. It would also help four million people eligible for assistance with Medicaid, which targets lower income residents, officials said.
But the last-gasp plan appears unlikely to survive given that Trump's incoming health secretary, Robert F. Kennedy Jr., has previously spoken out against the use of anti-obesity drugs.
In October Kennedy opposed a separate bill in Congress that would have expanded access to the medications, saying the money needed to do that would be better spent on improving nutrition.
"If we spent about one fifth of that giving good food, three meals a day to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight," Kennedy said on Fox News.
- 'So stupid' -
He also accused the Danish makers of Ozempic and Wegovy, Novo Nordisk, of "counting on selling it to Americans, because we're so stupid and addicted to drugs."
Kennedy has attracted major controversy for his anti-vaccine activism and embrace of conspiracy theories -- but some of his proposals for improving American's diets have won praise from health campaigners and lawmakers.
Any plan to increase US public health insurance spending would also likely run foul of Trump's bid to slash government budgets and waste.
Trump said last week as he appointed celebrity TV doctor Mehmet Oz to head Medicare and Medicaid that Oz would "cut waste and fraud" in what he called "our Country's most expensive Government Agency."
The Republican has also named tech tycoon Elon Musk and entrepreneur Vivek Ramaswamy to head a so called "government efficiency" commission to cut costs across government.
Biden has taken a different tack during his sole term in office.
The Democrat has led a major drive to lower the exorbitant cost of US prescription medicines, and his success in forcing pharmaceutical giants to reduce the prices of some became a key plank of his reelection campaign before he dropped out in July.
In July, Biden called on Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs, saying firms must stop "ripping off the American people."
X.AbuJaber--SF-PST